A Single Arm, Open-label, Long-term Efficacy and Safety Study of Romiplostim in Thrombocytopenic Pediatric Subjects With Immune Thrombocytopenia (ITP)
Phase of Trial: Phase III
Latest Information Update: 14 Nov 2019
Price : $35 *
At a glance
- Drugs Romiplostim (Primary)
- Indications Idiopathic thrombocytopenic purpura
- Focus Registrational; Therapeutic Use
- Sponsors Amgen
- 05 Sep 2019 Status changed from active, no longer recruiting to completed.
- 29 Aug 2019 This trial has been completed in France.
- 08 Aug 2019 Planned End Date changed from 23 Sep 2019 to 15 Aug 2019.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History